YINGMEI LEE: Open Payments
NPI 1831973692 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,010 in 70 payments from 16 companies in 2025. Trend: 2023 $116 · 2024 $2,108 · 2025 $2,010
Food & beverage: $2,010
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $452 |
| Enterra Medical, Inc. | 2 | $340 |
| Janssen Biotech, Inc. | 7 | $244 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $192 |
| PFIZER INC. | 9 | $160 |
| Madrigal Pharmaceuticals | 3 | $95 |
| GENZYME CORPORATION | 4 | $88 |
| Lilly USA, LLC | 3 | $83 |
| Celltrion USA Inc. | 4 | $82 |
| Gilead Sciences, Inc. | 3 | $71 |
Products named: SKYRIZI, TREMFYA, RINVOQ, ENTYVIO, REZDIFFRA, DUPIXENT, XELJANZ, OMVOH.
Industry payments across NV — which companies pay providers there.
